{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:57:00Z","timestamp":1790110620413,"version":"4.0.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T00:00:00Z","timestamp":1375747200000},"content-version":"vor","delay-in-days":36,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.sleep.2013.05.016","type":"journal-article","created":{"date-parts":[[2013,7,13]],"date-time":"2013-07-13T15:15:59Z","timestamp":1373728559000},"page":"675-684","source":"Crossref","is-referenced-by-count":256,"title":["The long-term treatment of restless legs syndrome\/Willis\u2013Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group"],"prefix":"10.1016","volume":"14","author":[{"given":"Diego","family":"Garcia-Borreguero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Kohnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Silber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Winkelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Earley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"H\u00f6gl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Manconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Montplaisir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2013.05.016_b0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1389-9457(03)00010-8","article-title":"Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health","volume":"4","author":"Allen","year":"2003","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0010","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00063-005-1097-y","article-title":"Quality of life in restless legs syndrome. Influence of daytime sleepiness and fatigue","volume":"100","author":"Gerhard","year":"2005","journal-title":"Med Klin (Munich)"},{"key":"10.1016\/j.sleep.2013.05.016_b0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mds.22753","article-title":"Quality of life score is primarily affected by the mental rather than the physical component in patients with restless legs syndrome","volume":"25","author":"Giannaki","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2013.05.016_b0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.sleep.2008.01.002","article-title":"Assessing health-related quality of life in patients with restless legs syndrome","volume":"10","author":"Happe","year":"2009","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.sleep.2006.03.014","article-title":"Predictors of health-related quality of life in sufferers with restless legs syndrome: a multi-national study","volume":"8","author":"McCrink","year":"2007","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.sleep.2010.07.007","article-title":"Restless legs syndrome: understanding its consequences and the need for better treatment","volume":"11","author":"Earley","year":"2010","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0035","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/sleep\/22.7.961","article-title":"Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the American Academy of Sleep Medicine","volume":"22","author":"Chesson","year":"1999","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2013.05.016_b0040","first-page":"970","article-title":"The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review","volume":"22","author":"Hening","year":"1999","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2013.05.016_b0045","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/sleep\/27.3.560","article-title":"An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder","volume":"27","author":"Hening","year":"2004","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2013.05.016_b0050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/sleep\/27.3.557","article-title":"Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder","volume":"27","author":"Littner","year":"2004","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2013.05.016_b0055","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/j.1468-1331.2006.01410.x","article-title":"EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep","volume":"13","author":"Vignatelli","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.sleep.2013.05.016_b0060","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/mds.22254","article-title":"Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice","volume":"23","author":"Trenkwalder","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2013.05.016_b0065","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1468-1331.2012.03853.x","article-title":"European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society","volume":"19","author":"Garcia-Borreguero","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.sleep.2013.05.016_b0070","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1212\/WNL.46.1.92","article-title":"A questionnaire study of 138 patients with restless legs syndrome: the \u2018Night-Walkers\u2019 survey","volume":"46","author":"Walters","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2013.05.016_b0075","series-title":"Evidence Report\/Technology Assessment No. 47 (Prepared by the Research Triangle Institute-University of North Carolina Evidence-based Practice Center under Contract No. 290-97-0011)","article-title":"Systems to rate the strength of scientific evidence","author":"West","year":"2002"},{"key":"10.1016\/j.sleep.2013.05.016_b0080","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1468-1331.2004.00867.x","article-title":"Guidance for the preparation of neurological management guidelines by EFNS scientific task forces\u2014revised recommendations 2004","volume":"11","author":"Brainin","year":"2004","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.sleep.2013.05.016_b0085","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.sleep.2010.12.007","article-title":"Efficacy and augmentation during 6months of double-blind pramipexole for restless legs syndrome","volume":"12","author":"H\u00f6gl","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0090","first-page":"S576","article-title":"Long-term efficacy and augmenation assessment of an \u03b12\u03b4 ligand (pregabalin) compared with a dopamine agonist (pramipexole) in restless legs syndrome: results of a randomized, double-bline, placebo-controlled trial","volume":"27","author":"Allen","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2013.05.016_b0095","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/mds.20983","article-title":"Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome","volume":"21","author":"Trenkwalder","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2013.05.016_b0100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jns.2010.04.003","article-title":"Long-term open-label study of pramipexole in patients with primary restless legs syndrome","volume":"294","author":"Inoue","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.sleep.2013.05.016_b0105","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.sleep.2007.12.004","article-title":"Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study)","volume":"9","author":"Partinen","year":"2008","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0110","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.sleep.2012.08.004","article-title":"Long-term use of pramipexole in the management of restless legs syndrome","volume":"13","author":"Lipford","year":"2012","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0115","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/j.1468-1331.2006.01459.x","article-title":"Long-term treatment with pramipexole in restless legs syndrome","volume":"13","author":"Montplaisir","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.sleep.2013.05.016_b0120","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/sleep\/26.7.819","article-title":"Pramipexole in the management of restless legs syndrome: an extended study","volume":"26","author":"Silber","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2013.05.016_b0125","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.sleep.2010.11.002","article-title":"A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome","volume":"12","author":"Silver","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2003.07.005","article-title":"Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS)","volume":"5","author":"Winkelman","year":"2004","journal-title":"Sleep Med"},{"issue":"Suppl. 1","key":"10.1016\/j.sleep.2013.05.016_b0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1468-1331.2000.0070s1027.x","article-title":"Pramipexole in the treatment of restless legs syndrome: a follow-up study","volume":"7","author":"Montplaisir","year":"2000","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.sleep.2013.05.016_b0140","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/archneur.61.9.1393","article-title":"Long-term treatment of restless legs syndrome with dopamine agonists","volume":"61","author":"Ondo","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.sleep.2013.05.016_b0145","unstructured":"Glaxo-SmithKline. A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe restless legs syndrome. unpublished 2008; ROR104836."},{"key":"10.1016\/j.sleep.2013.05.016_b0150","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/mds.21050","article-title":"Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial","volume":"21","author":"Montplaisir","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2013.05.016_b0155","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.sleep.2006.09.009","article-title":"A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome","volume":"8","author":"Garcia-Borreguero","year":"2007","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0160","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/mds.24889","article-title":"Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis\u2013Ekbom disease): results from a prospective, multicenter study over 66 weeks","volume":"27","author":"Garcia-Borreguero","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2013.05.016_b0165","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/1531-8257(199909)14:5<890::AID-MDS1037>3.0.CO;2-Q","article-title":"Ropinirole and restless legs syndrome","volume":"14","author":"Galvez-Jimenez","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2013.05.016_b0170","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/mds.23157","article-title":"Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States","volume":"25","author":"Hening","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2013.05.016_b0175","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(08)70112-1","article-title":"Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Trenkwalder","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.sleep.2013.05.016_b0180","first-page":"A251","article-title":"Long-term treatment with transdermal rotigotine in patients with idiopathic restless legs syndrome (RLS): results from a 12-month open-label extension trial","volume":"33","author":"Allen","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2013.05.016_b0185","first-page":"250","article-title":"Safety and efficacy of long-term treatment with transdermal rotigotine in patients with idiopathic restless legs syndrome: a 12-month open-label extension study","volume":"19","author":"Ferini-Strambi","year":"2010","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2013.05.016_b0190","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1474-4422(11)70127-2","article-title":"Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study","volume":"10","author":"Oertel","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.sleep.2013.05.016_b0195","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/mds.1104","article-title":"Piribedil for restless legs syndrome: a pilot study","volume":"16","author":"Evidente","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2013.05.016_b0200","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/mds.21401","article-title":"Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial","volume":"22","author":"Trenkwalder","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2013.05.016_b0205","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S1389-9457(07)70252-6","article-title":"Double-blind, multi-centre, 2-year long-term study comparing treatment with cabergoline and levodopa in severe restless legs syndrome","volume":"8","author":"H\u00f6gl","year":"2007","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0210","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00415-009-5299-8","article-title":"Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study","volume":"257","author":"H\u00f6gl","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.sleep.2013.05.016_b0215","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/mds.10503","article-title":"One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?","volume":"18","author":"Trenkwalder","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2013.05.016_b0220","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/sleep\/19.10.801","article-title":"Pergolide and carbidopa\/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients","volume":"19","author":"Earley","year":"1996","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2013.05.016_b0225","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archneur.1982.00510230065027","article-title":"Treatment of restless legs syndrome with levodopa plus benserazide","volume":"39","author":"Akpinar","year":"1982","journal-title":"Arch Neurol"},{"key":"10.1016\/j.sleep.2013.05.016_b0230","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4065\/77.12.1280","article-title":"Valvular heart disease in patients taking pergolide","volume":"77","author":"Pritchett","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.sleep.2013.05.016_b0235","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0240","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/01.wnl.0000238508.68593.1d","article-title":"Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study","volume":"67","author":"Yamamoto","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2013.05.016_b0245","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1017\/S0317167100008593","article-title":"Pergolide associated cardiac valvulopathy based on Ontario administrative data","volume":"35","author":"Zadikoff","year":"2008","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.sleep.2013.05.016_b0250","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4065\/mcp.2009.0700","article-title":"Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study","volume":"85","author":"Bogan","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.sleep.2013.05.016_b0255","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WNF.0b013e3182087d48","article-title":"A 52-week study of gabapentin enacarbil in restless legs syndrome","volume":"34","author":"Ellenbogen","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.sleep.2013.05.016_b0260","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.pnpbp.2011.10.009","article-title":"Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients","volume":"36","author":"Inoue","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.sleep.2013.05.016_b0265","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1600-0404.2007.00796.x","article-title":"Pregabalin in restless legs syndrome with and without neuropathic pain","volume":"115","author":"Sommer","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.sleep.2013.05.016_b0270","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/sleep\/19.3.224","article-title":"Management of restless legs syndrome with gabapentin (Neurontin)","volume":"19","author":"Mellick","year":"1996","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2013.05.016_b0275","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00002826-199704000-00006","article-title":"Treatment of restless legs syndrome with gabapentin","volume":"20","author":"Adler","year":"1997","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.sleep.2013.05.016_b0280","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4088\/JCP.v60n0407","article-title":"Treatment of restless legs syndrome with tramadol: an open study","volume":"60","author":"Lauerma","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.sleep.2013.05.016_b0285","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/mds.20359","article-title":"Methadone for refractory restless legs syndrome","volume":"20","author":"Ondo","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2013.05.016_b0290","doi-asserted-by":"crossref","first-page":"E263","DOI":"10.1227\/01.NEU.0000311089.04014.91","article-title":"Control of medically refractory restless legs syndrome with intrathecal morphine: case report","volume":"62","author":"Ross","year":"2008","journal-title":"Neurosurgery"},{"key":"10.1016\/j.sleep.2013.05.016_b0295","doi-asserted-by":"crossref","first-page":"E1209","DOI":"10.1227\/01.NEU.0000325674.02282.CC","article-title":"Intrathecal morphine as a treatment for refractory restless legs syndrome","volume":"63","author":"Lindvall","year":"2008","journal-title":"Neurosurgery"},{"key":"10.1016\/j.sleep.2013.05.016_b0300","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1034\/j.1399-6576.2002.460121.x","article-title":"Successful treatment of restless legs syndrome with an implanted pump for intrathecal drug delivery","volume":"46","author":"Jakobsson","year":"2002","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.sleep.2013.05.016_b0305","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/mds.1214","article-title":"Long-term follow-up on restless legs syndrome patients treated with opioids","volume":"16","author":"Walters","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2013.05.016_b0310","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.sleep.2010.05.009","article-title":"Effect of tetrabenazine use on restless legs syndrome","volume":"11","author":"Ondo","year":"2010","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0315","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.sleep.2007.12.006","article-title":"A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome","volume":"10","author":"Earley","year":"2009","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0320","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/mds.22562","article-title":"A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome","volume":"24","author":"Grote","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.sleep.2013.05.016_b0325","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.sleep.2011.06.009","article-title":"Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial","volume":"12","author":"Allen","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0330","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0002-9343(97)89493-4","article-title":"Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults","volume":"100","author":"Schenck","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0335","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/jnnp.2005.075671","article-title":"Levetiracetam can be effective in the treatment of restless legs syndrome with periodic limb movements in sleep: report of two cases","volume":"77","author":"Della Marca","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.sleep.2013.05.016_b0340","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.sleep.2008.11.003","article-title":"Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebo-controlled study","volume":"10","author":"Wang","year":"2009","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0345","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4065\/79.7.916","article-title":"Medical Advisory Board of the Restless Legs Syndrome Foundation. An algorithm for the management of restless legs syndrome","volume":"79","author":"Silber","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.sleep.2013.05.016_b0350","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.sleep.2007.03.022","article-title":"Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute","volume":"8","author":"Garcia-Borreguero","year":"2007","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0355","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.sleep.2010.08.001","article-title":"Loss of response during long-term treatment of restless legs syndrome: guidelines approved by the International Restless Legs Syndrome Study Group for use in clinical trials","volume":"11","author":"Garcia-Borreguero","year":"2010","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0360","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.sleep.2006.05.011","article-title":"Restless legs syndrome augmentation associated with tramadol","volume":"7","author":"Earley","year":"2006","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2013.05.016_b0365","first-page":"81","article-title":"Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study","volume":"33","author":"Cornelius","year":"2010","journal-title":"Sleep"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945713002116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945713002116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:27:18Z","timestamp":1563409638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945713002116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":73,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1389945713002116"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2013.05.016","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}